Global Internal Radiation Therapy Market Size By Type (Brachytherapy, Systemic Radiation Therapy), By Application (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Internal Radiation Therapy Market was valued at USD 5.3 billion in 2023 and is projected to surpass USD 9.7 billion by 2031, expanding at a CAGR of 7.6% during the forecast period from 2023 to 2031. This growth is primarily driven by the increasing prevalence of cancer, advancements in radiation technology, and the growing adoption of minimally invasive treatment options. Internal radiation therapy, or brachytherapy, offers a highly localized form of cancer treatment that minimizes damage to surrounding healthy tissues, making it a preferred choice in modern oncology.

Drivers:

1. Rising Cancer Incidence Globally:

The growing global burden of cancer, particularly prostate, cervical, and breast cancers, is significantly boosting demand for internal radiation therapy as a targeted treatment modality.

2. Technological Advancements in Brachytherapy Equipment:

Improvements in imaging-guided and intensity-modulated brachytherapy systems are enhancing treatment precision, driving wider adoption in both developed and emerging healthcare markets.

3. Growing Preference for Minimally Invasive Procedures:

Internal radiation therapy offers fewer complications, reduced hospital stays, and quicker recovery times, making it increasingly preferred over conventional external beam radiation.

Restraints:

1. High Costs and Limited Accessibility in Developing Regions:

The high setup and maintenance costs associated with advanced brachytherapy systems can hinder their adoption in low-resource settings.

2. Shortage of Skilled Oncologists and Radiologists:

Delivering internal radiation therapy requires specialized training. A limited pool of trained personnel in many regions remains a significant bottleneck.

Opportunity:

1. Market Expansion in Emerging Economies:

Growing investment in healthcare infrastructure and increasing awareness about cancer treatment options in Asia-Pacific and Latin America offer strong growth prospects.

2. Integration of AI and Image-Guidance:

Combining brachytherapy systems with AI-driven imaging and planning tools presents an opportunity to optimize treatment outcomes and enhance clinical efficiency.

Market by System Type Insights:

The market is segmented into High-Dose Rate (HDR) Brachytherapy and Low-Dose Rate (LDR) Brachytherapy. In 2023, the HDR segment held the largest share owing to its shorter treatment duration and increasing application across various cancer types. However, the LDR segment continues to be relevant in prostate cancer treatment due to its effectiveness in low-risk cases and ease of use.

Market by End-use Insights:

Hospitals dominated the end-use segment in 2023, accounting for more than 50% of the global market share. Hospitals are primary centers for cancer diagnosis and treatment and are increasingly equipped with advanced brachytherapy units. Cancer specialty clinics are expected to show notable growth due to rising outpatient treatment trends and technological integration.

Market by Regional Insights:

North America led the market in 2023, driven by high healthcare expenditure, advanced oncology infrastructure, and favorable reimbursement policies. Asia-Pacific is poised to witness the highest CAGR during the forecast period due to a rising cancer burden, government initiatives to improve cancer care, and increasing accessibility to advanced treatment technologies in countries like India and China.

Competitive Scenario:

Key players in the global internal radiation therapy market include Varian Medical Systems (a Siemens Healthineers company), Elekta AB, Eckert & Ziegler BEBIG, Isoray Medical Inc., Theragenics Corporation, CIVCO Radiotherapy, and Becton, Dickinson and Company. These companies are focused on innovation, global expansion, and strategic partnerships to enhance their competitive edge.

Key Developments:

In 2023, Varian launched an AI-enhanced brachytherapy planning platform to streamline dose calculation and improve accuracy.

In 2024, Elekta partnered with a major oncology hospital network in Asia to deploy next-generation HDR systems.

In 2025, Isoray received regulatory approval for a novel Cesium-131-based seed implant system, broadening its prostate cancer treatment offerings.

Scope of Work – Global Internal Radiation Therapy Market

Report Metric Details

Market Size (2023) USD 5.3 billion

Projected Market Size (2031) USD 9.7 billion

CAGR (2023–2031) 7.6%

Market Segments By System Type (HDR, LDR), By End-use (Hospitals, Specialty Clinics)

Growth Drivers Rising cancer incidence, tech advancements, minimally invasive treatment

Opportunities AI integration, expansion in emerging markets

FAQs:

1) What is the current market size of the Global Internal Radiation Therapy Market?

The market was valued at USD 5.3 billion in 2023.

2) What is the major growth driver of the Global Internal Radiation Therapy Market?

The primary growth driver is the rising incidence of cancer and advancements in radiation treatment technologies.

3) Which is the largest region during the forecast period in the Global Internal Radiation Therapy Market?

North America is the largest regional market due to high healthcare spending and advanced treatment infrastructure.

4) Which segment accounted for the largest market share in the Global Internal Radiation Therapy Market?

The High-Dose Rate (HDR) Brachytherapy segment held the largest share in 2023.

5) Who are the key market players in the Global Internal Radiation Therapy Market?

Key players include Varian Medical Systems, Elekta AB, Eckert & Ziegler BEBIG, Isoray, and Theragenics Corporation.